Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SkinMedica Inc.

This article was originally published in Start Up

Executive Summary

SkinMedica Inc. is a specialty pharmaceuticals company focused on the skin care and dermatology markets. It is amassing a portfolio of branded prescription products and promising late-stage candidates, funded in part, by revenues from cosmeceutical sales.

You may also be interested in...



The Rebirth of Dermagraft

Dermagraft is often mentioned as an example of a failure in tissue engineering, illustrating the difficulty of achieving return on investment in this field. The product was only a market failure, however; clinicians say that it worked to heal difficult wounds, and that it was just a product ahead of its time. Now small company Advanced BioHealing has given new life to the bioengineered dermal substitute, abandoned by Smith & Nephew, by supporting it with the focus, and the unique marketing and manufacturing skills that tissue-engineered products require. In the process, it believes it has created assets and skill-sets from which other tissue-engineering start-ups might benefit.

Dermatology Start-Ups

Judging from the number of recent well-financed company launches and the size of follow-on rounds for established players, specialty dermatology hasn't lost its allure for investors. Add to that two successful 2004 IPOs--for Barrier Therapeutics Inc. and Cutera Inc.--and it's clear that aesthetic and therapeutic dermatology are still good bases for building specialty pharmaceutical businesses.

Chester Valley Pharmaceuticals Inc.

In a year that saw a number of significant private financings in dermatology, Chester Valley Pharmaceuticals Inc. was one of the standouts. The specialty pharma was formed in November 2004 by dermatology industry veterans Robert J. Moccia and Xavier Yon, and by private equity firm GTCR Golder Rauner LLC, which has made a $75 million equity commitment to the new company.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090803

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel